Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD). It is also developing IP2018, a monoamine reuptake inhibitor that is in Phase IIb for the treatment of psychogenic erectile dysfunction and in preclinical development for the treatment of FSD, as well as IP2016, which is in preclinical development for the treatment of depression and pain. The company was incorporated in 2016 and is headquartered in Copenhagen, Denmark.